Protara Therapeutics Inc TARA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.30 up $0.17, 7.98% at close Nov 6
Last close · Previous close $2.13
- Market cap
- $129.27MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.36Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$2.30up $0.17, 7.98%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.13Nov 5
- Volume690.55KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume946.57KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.09 to $7.82; now $2.30
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
TARA trailed the S&P 500 in all 7 periods.
| Period | TARA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TARA: down 10.0% S&P 500: down 5.6% | TARA trailed the S&P 500 by 4.4 percentage points Trailed |
| 3M | TARA: down 43.9% S&P 500: down 4.1% | TARA trailed the S&P 500 by 39.8 percentage points Trailed |
| YTD | TARA: down 56.8% S&P 500: up 8.7% | TARA trailed the S&P 500 by 65.5 percentage points Trailed |
| 1Y | TARA: down 46.4% S&P 500: up 10.9% | TARA trailed the S&P 500 by 57.3 percentage points Trailed |
| Long term | ||
| 3Y | TARA: up 67.9% S&P 500: up 75.0% +18.9% vs +20.5% a year | TARA trailed the S&P 500 by 7.1 percentage points Trailed |
| 5Y | TARA: down 67.8% S&P 500: up 67.8% −20.3% vs +10.9% a year | TARA trailed the S&P 500 by 135.6 percentage points Trailed |
| 10Y | TARA: down 99.3% S&P 500: up 313.1% −38.9% vs +15.2% a year | TARA trailed the S&P 500 by 412.4 percentage points Trailed |
$10,000 invested in TARA 10 years ago (Nov 4, 2016) would be worth about $72 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
TARA trailed the S&P 500 in all 7 periods.
| Period | TARA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TARA: down 10.0% S&P 500: down 5.6% | TARA trailed the S&P 500 by 4.4 percentage points Trailed |
| 3M | TARA: down 43.9% S&P 500: down 4.3% | TARA trailed the S&P 500 by 39.6 percentage points Trailed |
| YTD | TARA: down 56.8% S&P 500: up 7.8% | TARA trailed the S&P 500 by 64.6 percentage points Trailed |
| 1Y | TARA: down 46.4% S&P 500: up 9.7% | TARA trailed the S&P 500 by 56.1 percentage points Trailed |
| Long term | ||
| 3Y | TARA: up 67.9% S&P 500: up 68.8% +18.9% vs +19.1% a year | TARA trailed the S&P 500 by 0.9 percentage points Trailed |
| 5Y | TARA: down 67.8% S&P 500: up 56.9% −20.3% vs +9.4% a year | TARA trailed the S&P 500 by 124.7 percentage points Trailed |
| 10Y | TARA: down 99.3% S&P 500: up 252.6% −38.9% vs +13.4% a year | TARA trailed the S&P 500 by 351.9 percentage points Trailed |
$10,000 invested in TARA 10 years ago (Nov 4, 2016) would be worth about $72 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$800.00
Closing high on . Now 99.7% below that record.
Split-adjusted daily closes since Oct 22, 2014.
Stock splits
1
1-for-40 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$1.36 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 0.8×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −51.44%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$10.48MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own TARA DCF in Excel. Value Protara Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$70.02M
- Diluted EPS
- −$1.36
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$11.22M | −$0.50 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$12.77M | −$0.43 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$11.91M | −$0.29 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$14.96M | −$0.35 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$13.26M | −$0.31 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$17.31M | −$0.38 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$17.78M | −$0.31 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$21.67M | −$0.36 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$47.25M | −$4.21 |
| FY22 (Dec 31, 2022) | $0.00 | −$65.95M | −$5.86 |
| FY23 (Dec 31, 2023) | $0.00 | −$40.42M | −$3.57 |
| FY24 (Dec 31, 2024) | $0.00 | −$44.60M | −$2.17 |
| FY25 (Dec 31, 2025) | $0.00 | −$57.44M | −$1.34 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$66.49MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$66.13MLast 12 months
- Capital spending$360.00KLast 12 months
Shareholder returns
- $82.39MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $162.60MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$2.75MAs of Jun 30, 2026
- Net cash$159.85MAs of Jun 30, 2026
- 10.97As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.02As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −41.7%Last 12 months
Over the last 12 months, Protara Therapeutics lost money: its net loss was 41.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −38.8%Last 12 months
Over the last 12 months, Protara Therapeutics’s net loss was 38.8% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Protara Therapeutics Inc
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
TARA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
TARA stock FAQ
What is TARA stock’s price today?
Protara Therapeutics (TARA) traded at $2.30 at the close on , up $0.17 (7.98%) from the previous close of $2.13. Over the past 52 weeks it has traded between $2.09 and $7.82.
If you invested $1,000 in TARA 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in TARA on would be worth about $7 at the close on , a total return of −99.3%. The same $1,000 would be worth $322 if invested five years ago and $536 if invested one year ago. Past performance doesn’t predict future returns.
What is Protara Therapeutics’s market cap?
Protara Therapeutics’s market capitalization is about $129.3 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $2.30 (how market cap works). Protara Therapeutics reported 56.20M shares outstanding at the end of its latest quarter ().
What is TARA’s P/E ratio?
TARA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.36).
What are TARA’s earnings per share?
TARA’s diluted earnings per share were −$1.36 over the four quarters to , compared with −$1.57 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.36 per share, against −$0.35 a year earlier (how EPS works).
Does TARA pay a dividend?
Protara Therapeutics hasn’t paid a dividend in the last twelve months.
What is TARA’s 52-week high and low?
Over the past 52 weeks TARA has traded as low as $2.09 and as high as $7.82. At $2.30 at the close on , it is 70.6% below that high and 10.0% above the low.
What is TARA’s all-time high?
TARA’s highest closing price was $800.00 on , adjusted for stock splits. At $2.30 at the close on , it is 99.7% below that record.
Has TARA stock ever split?
Yes, once: 1-for-40 on .
How has TARA stock performed?
Including dividends and measured to the close on , TARA has returned −56.8% so far this year and −46.4% over the past year, and −67.8% over five years (−20.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Protara Therapeutics in?
Protara Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does TARA trade on?
Protara Therapeutics trades on the Nasdaq under the ticker symbol TARA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.